SCHEMBL413698

SCHEMBL413698

CCOC(=O)CN(C)Cc1cccc(N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
LTA4H P09960 2/20 0.44
HSD11B1 P28845 1/20 0.44
MEP1B Q16820 1/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CD274 Q9NZQ7 2/20 0.39
PDCD1 Q15116 1/20 0.39
F10 P00742 1/20 0.38
AOC3 Q16853 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
PPIB P23284 1/20 0.37
PPIA P62937 1/20 0.37
PPID Q08752 1/20 0.37
PPIG Q13427 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10076568 0.86 KMT2A (0.49) SMN1; SMN2ALDH1A1KDM4EMAPTLTA4H
SCHEMBL13244170 0.84 ALOX5 (0.48) SMN1; SMN2ALDH1A1LTA4HHSD11B1MEN1
SCHEMBL3147669 0.82 PPID (0.50) SMN1; SMN2ALDH1A1KDM4EMAPTLTA4H
SCHEMBL8337648 0.82 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1KDM4EMAPTLTA4H
SCHEMBL10053129 0.81 MEN1 (0.46) SMN1; SMN2ALDH1A1KDM4EMAPTLTA4H
SCHEMBL13742232 0.81 HSD11B1 (0.49) ALDH1A1KDM4ELTA4HHSD11B1MEN1
SCHEMBL274133 0.79 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL274132 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1MAPTF10L3MBTL1
SCHEMBL15338792 0.77 HSD11B1 (0.46) ALDH1A1HSD11B1MEN1KMT2AAOC3
SCHEMBL1068218 0.77 CYP4F2 (0.55) SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394955-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2013-03-12 US disclosed
US-8394955-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2013-03-12 US disclosed
US-8148388-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-04-03 US disclosed
US-8148388-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-04-03 US disclosed
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2012-03-15 US disclosed
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2012-03-15 US disclosed
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-24 US disclosed
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR0B1, NR1H3, NCOA3 SMN1; SMN2 4387/4885ALDH1A1 1457/4885KDM4E 3842/4885
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR1H3, NR1H2, NR0B1 SMN1; SMN2 4526/4885ALDH1A1 1741/4885KDM4E 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.